A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Conditions
Advanced Squamous Tumors
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City Of Hope Comprehensive Cancer Center /ID# 276550, Duarte, California, United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432, Irvine, California, United States
University of Chicago Medical Center /ID# 276638, Chicago, Illinois, United States
START Midwest /ID# 272505, Grand Rapids, Michigan, United States
Carolina BioOncology Institute /ID# 272380, Huntersville, North Carolina, United States
Next Oncology - Irving /ID# 276659, Irving, Texas, United States
Princess Margaret Cancer Centre /ID# 276852, Toronto, Ontario, Canada
The Chaim Sheba Medical Center /ID# 276798, Ramat Gan, Tel Aviv, Israel
Rambam Health Care Campus- Haifa /ID# 276799, Haifa, Israel
Hadassah Medical Center-Hebrew University /ID# 276800, Jerusalem, Israel
National Cancer Center Hospital East /ID# 276585, Kashiwa-shi, Chiba, Japan
Kansai Medical University Hospital /ID# 276586, Hirakata-shi, Osaka, Japan
Study leads
ABBVIE INC.
Study Director
AbbVie